Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

macrocycle-bridged STING agonist E7766

An agonist of macrocycle-bridged stimulator of interferon genes (STING) protein, with potential immunoactivating and antineoplastic activities. Upon intravenous administration, macrocycle-bridged STING agonist (MBSA) E7766 targets and binds to STING and activates the STING pathway, which promotes IKK-related kinase TANK-binding kinase 1 (TBK1) signaling and activates nuclear factor-kappa B (NF-kB) and interferon regulatory factor 3 (IRF3) in immune cells in the tumor microenvironment (TME). This leads to the production of pro-inflammatory cytokines, including interferons (IFNs). Specifically, expression of IFN-beta (IFNb) enhances the cross-presentation of tumor-associated antigens (TAAs) by CD8alpha-positive and CD103-positive dendritic cells (DCs) to cytotoxic T lymphocytes (CTLs). This results in a CTL-mediated immune response against tumor cells and causes tumor cell lysis. Compared to conventional STING agonists, MBSA E7766 allows for conformational rigidity of the unique macrocycle bridge which enhances its stability and STING affinity, thereby increasing its efficacy.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:stimulator of interferon genes agonist E7766
Sting agonist E7766
Code name:E 7766
E-7766
E7766
MBSA E7766
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search